Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study.
Identifieur interne : 001018 ( PubMed/Corpus ); précédent : 001017; suivant : 001019Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study.
Auteurs : B. Rousseau ; P. Loulergue ; O. Mir ; A. Krivine ; S. Kotti ; E. Viel ; T. Simon ; A. De Gramont ; F. Goldwasser ; O. Launay ; C. TournigandSource :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2012.
English descriptors
- KwdEn :
- Aged, Antibodies, Monoclonal (administration & dosage), Antineoplastic Agents (administration & dosage), Female, Humans, Influenza A Virus, H1N1 Subtype, Influenza Vaccines (immunology), Influenza Vaccines (therapeutic use), Influenza, Human (complications), Influenza, Human (prevention & control), Influenza, Human (virology), Male, Middle Aged, Neoplasms (complications), Neoplasms (immunology), Neoplasms (therapy), Prospective Studies.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Antineoplastic Agents.
- chemical , immunology : Influenza Vaccines.
- chemical , therapeutic use : Influenza Vaccines.
- complications : Influenza, Human, Neoplasms.
- immunology : Neoplasms.
- prevention & control : Influenza, Human.
- therapy : Neoplasms.
- virology : Influenza, Human.
- Aged, Female, Humans, Influenza A Virus, H1N1 Subtype, Male, Middle Aged, Prospective Studies.
Abstract
Influenza vaccination is recommended to cancer patients undergoing chemotherapy, but vaccine coverage remains low. During the 2009 influenza pandemic, French recommendations were to vaccinate immunocompromised patients with two doses of adjuvanted vaccine. This study aimed to evaluate vaccine immunogenicity in cancer patients receiving chemotherapy.
DOI: 10.1093/annonc/mdr141
PubMed: 21576285
Links to Exploration step
pubmed:21576285Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study.</title><author><name sortKey="Rousseau, B" sort="Rousseau, B" uniqKey="Rousseau B" first="B" last="Rousseau">B. Rousseau</name><affiliation><nlm:affiliation>Oncology Unit, Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Loulergue, P" sort="Loulergue, P" uniqKey="Loulergue P" first="P" last="Loulergue">P. Loulergue</name></author><author><name sortKey="Mir, O" sort="Mir, O" uniqKey="Mir O" first="O" last="Mir">O. Mir</name></author><author><name sortKey="Krivine, A" sort="Krivine, A" uniqKey="Krivine A" first="A" last="Krivine">A. Krivine</name></author><author><name sortKey="Kotti, S" sort="Kotti, S" uniqKey="Kotti S" first="S" last="Kotti">S. Kotti</name></author><author><name sortKey="Viel, E" sort="Viel, E" uniqKey="Viel E" first="E" last="Viel">E. Viel</name></author><author><name sortKey="Simon, T" sort="Simon, T" uniqKey="Simon T" first="T" last="Simon">T. Simon</name></author><author><name sortKey="De Gramont, A" sort="De Gramont, A" uniqKey="De Gramont A" first="A" last="De Gramont">A. De Gramont</name></author><author><name sortKey="Goldwasser, F" sort="Goldwasser, F" uniqKey="Goldwasser F" first="F" last="Goldwasser">F. Goldwasser</name></author><author><name sortKey="Launay, O" sort="Launay, O" uniqKey="Launay O" first="O" last="Launay">O. Launay</name></author><author><name sortKey="Tournigand, C" sort="Tournigand, C" uniqKey="Tournigand C" first="C" last="Tournigand">C. Tournigand</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:21576285</idno><idno type="pmid">21576285</idno><idno type="doi">10.1093/annonc/mdr141</idno><idno type="wicri:Area/PubMed/Corpus">001018</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001018</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study.</title><author><name sortKey="Rousseau, B" sort="Rousseau, B" uniqKey="Rousseau B" first="B" last="Rousseau">B. Rousseau</name><affiliation><nlm:affiliation>Oncology Unit, Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Loulergue, P" sort="Loulergue, P" uniqKey="Loulergue P" first="P" last="Loulergue">P. Loulergue</name></author><author><name sortKey="Mir, O" sort="Mir, O" uniqKey="Mir O" first="O" last="Mir">O. Mir</name></author><author><name sortKey="Krivine, A" sort="Krivine, A" uniqKey="Krivine A" first="A" last="Krivine">A. Krivine</name></author><author><name sortKey="Kotti, S" sort="Kotti, S" uniqKey="Kotti S" first="S" last="Kotti">S. Kotti</name></author><author><name sortKey="Viel, E" sort="Viel, E" uniqKey="Viel E" first="E" last="Viel">E. Viel</name></author><author><name sortKey="Simon, T" sort="Simon, T" uniqKey="Simon T" first="T" last="Simon">T. Simon</name></author><author><name sortKey="De Gramont, A" sort="De Gramont, A" uniqKey="De Gramont A" first="A" last="De Gramont">A. De Gramont</name></author><author><name sortKey="Goldwasser, F" sort="Goldwasser, F" uniqKey="Goldwasser F" first="F" last="Goldwasser">F. Goldwasser</name></author><author><name sortKey="Launay, O" sort="Launay, O" uniqKey="Launay O" first="O" last="Launay">O. Launay</name></author><author><name sortKey="Tournigand, C" sort="Tournigand, C" uniqKey="Tournigand C" first="C" last="Tournigand">C. Tournigand</name></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Antineoplastic Agents (administration & dosage)</term><term>Female</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza Vaccines (immunology)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (complications)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Male</term><term>Middle Aged</term><term>Neoplasms (complications)</term><term>Neoplasms (immunology)</term><term>Neoplasms (therapy)</term><term>Prospective Studies</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Influenza, Human</term><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza vaccination is recommended to cancer patients undergoing chemotherapy, but vaccine coverage remains low. During the 2009 influenza pandemic, French recommendations were to vaccinate immunocompromised patients with two doses of adjuvanted vaccine. This study aimed to evaluate vaccine immunogenicity in cancer patients receiving chemotherapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21576285</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study.</ArticleTitle><Pagination><MedlinePgn>450-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdr141</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Influenza vaccination is recommended to cancer patients undergoing chemotherapy, but vaccine coverage remains low. During the 2009 influenza pandemic, French recommendations were to vaccinate immunocompromised patients with two doses of adjuvanted vaccine. This study aimed to evaluate vaccine immunogenicity in cancer patients receiving chemotherapy.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">VACANCE is a prospective open-label study that evaluated the immunogenicity and safety of two doses of AS03A-adjuvanted H1N1v vaccine in cancer patients receiving cytotoxic and/or targeted therapies. Serum haemagglutination-inhibited antibody titres against influenza A H1N1v were measured at days 1, 21, and 42, to estimate the proportion of participants with antibody titres ≥ 1 : 40 [seroprotection rate (SPR)], the efficacy of seroconversion, and factors that increased the geometric mean titre.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-five patients were included. At baseline, 5% of patients had vaccine strain titres of specific haemagglutination inhibition antibodies that were ≥ 1 : 40. After one and two doses of vaccine, SPRs were 48% and 73%, respectively, and seroconversion rates were 44% and 73%, respectively. Vaccine-related adverse events were mild to moderate.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A single dose of AS03-adjuvanted A/H1N1 vaccine triggered a low immune response in cancer patients on chemotherapy depending on their treatment type and frequency. Two doses are needed for these cancer patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Oncology Unit, Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loulergue</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mir</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Krivine</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kotti</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Viel</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>de Gramont</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Goldwasser</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Launay</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Tournigand</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21576285</ArticleId><ArticleId IdType="pii">S0923-7534(19)34397-2</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdr141</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001018 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001018 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21576285
|texte= Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21576285" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |